Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML

计划入组 18 人 · 首次发布于 2020 年 4 月 28 日

Phase 1 Trial of Intravenously Administered Nerofe™ in Subjects With Advanced Malignancies

计划入组 23 人 · 首次发布于 2012 年 9 月 24 日

NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors

计划入组 24 人 · 首次发布于 2022 年 12 月 22 日

Nerofe

C₉₆H₁₂₉N₂₁O₂₀

peroxy pyruvic acid

Vero-Vac

Jochen Vehoff

Switzerland

Verona Pharma

United Kingdom

Verona Pharma, Inc.

United States

Oasis Diagnostics Receives Michael J. Fox Foundation Grant for Saliva-Based Parkinson's Test

Rusfertide Achieves Primary Endpoint in Phase 3 VERIFY Trial for Polycythemia Vera

FDA Approves Verona Pharma's Ohtuvayre (ensifentrine) for COPD Maintenance